Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital cuts DCC price target

(Sharecast News) - RBC Capital Markets cut its price target on DCC on Monday to 5,200p from 5,400p as it tweaked forecasts to reflect a lower valuation for DCC Technology, given weaker trading and macro uncertainty. "Hence we see less upside than previous, but given a lack of value elsewhere at the defensive end of the sector, we remain at outperform, ahead of the cash return," the bank said. "However, this is certainly not a table thumper."

RBC said its adjusted EBITA forecasts move down around 1%, bearing in mind that it had already brought its DCC Technology forecasts down ahead of numbers to reflect tough trading and tariff uncertainty.

The bank said its earnings per share changes are immaterial but will be sensitive to the exact timing and price of the £100m buyback and £600m cash return. It assumes completion by mid financial year at the current share price.

RBC said the key sensitivity remains the value the market ascribes to DCC Energy.

"Greater disclosure is helpful, but there is a risk that the market continues to struggle to value it as DCC Energy is somewhat of a conglomerate and a unique proposition in itself," it said.

"Hence, there is a risk that a full break-up may be the only way to demonstrate value over the medium-term, in our view."

At 0945 BST, the shares were down 1% at 4,760p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.